Neurocrine Biosciences | NBIX - Ativos





Ativos Alterar Data
AbbVie USD 147.68B 12.57B 2026-09
Acadia Pharmaceuticals USD 1.79B 51.25M 2026-09
Agios Pharmaceuticals USD 1.06B 44.38M 2026-09
ALKERMES USD 4.44B 42.4M 2026-09
Alnylam Pharmaceuticals USD 7.99B 2.44B 2026-09
Amgen USD 96.05B 409M 2026-09
Biogen USD 32.05B 32.5M 2026-09
BioMarin Pharmaceutical USD 11.57B 154.21M 2026-09
Cytokinetics USD 1.82B 99.77M 2026-09
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Exelixis USD 2.51B 19.26M 2026-09
Gilead Sciences USD 51.41B 2.05B 2026-09
Halozyme Therapeutics USD 3.47B 895.94M 2026-09
Incyte USD 7.29B 585.39M 2026-09
Ionis Pharmaceuticals USD 2.91B 81.91M 2026-09
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Neurocrine Biosciences USD 5.63B 268.3M 2026-09
Pfizer USD 204.54B 3.41B 2026-09
Prothena USD 283.52M 19.06M 2026-09
Regeneron Pharmaceuticals USD 44.41B 2.67B 2026-09
Repligen USD 2.93B 23.77M 2026-09
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sarepta Therapeutics USD 3.17B 22.45M 2026-09
Teva Pharmaceutical Industries USD 40.04B 185M 2026-09
Ultragenyx Pharmaceutical USD 1.19B 77M 2026-09
Vertex Pharmaceuticals USD 32.74B 5.31B 2026-09